Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Chalice Brands Ltd CHALF

Chalice Brands Ltd. is a U.S. operator in the most competitive, innovative and mature cannabis market in North America. Leaders in retail, marketing and craft cultivation supported by fully integrated processing and distribution. The Company has 12 retail stores in Oregon operating as Chalice Farms, Homegrown Oregon and Left Coast Connection and is distributed nationally through Fifth & Root.


GREY:CHALF - Post by User

Bullboard Posts
Post by Interpolation1on Aug 11, 2016 9:36am
155 Views
Post# 25130151

FEDS REJECT .... NR ... CONFIRMED

FEDS REJECT .... NR ... CONFIRMED
Feds reject request to reclassify marijuana; say it's not a safe and effective medicine

 

WASHINGTON, Aug. 11 (UPI) --

The Drug Enforcement Administration on Thursday is expected to reject requests to reclassify marijuana, continuing the federal prohibition against the drug's use for medical purposes.

The DEA will turn down requests to remove marijuana from the Schedule I drug classification under the Controlled Substances Act.

Schedule I drugs are those considered to have a high potential for abuse, and no accepted medical use, and which it is therefore illegal to make, possess and distribute. They include LSD and heroin, along with marijuana.

Drug Enforcement Administration chief Chuck Rosenberg said the decision to keep marijuana on the Schedule I list is based on the Food and Drug Administration's conclusion that it has no currently accepted medical use in treatment in the United States.

This decision isn't based on danger. This decision is based on whether marijuana, as determined by the FDA, is a safe and effective medicine -- and it's not, Rosenberg said, adding that the DEA continues to support efforts to advance scientific research on marijuana.

The decision to keep marijuana as a Schedule I drug instead of Schedule II, a less strictly regulated category made up of drugs including highly addictive oxycodone and methamphetamine, will continue to divide the federal government from 25 states, as well as Washington, D.C., that have passed laws permitting the medical use of marijuana, with restrictions.

Five states are voting on the legalization of recreational marijuana use this November. The National Cannabis Industry Association said the DEA's decision flies in the face of objective science and overwhelming public opinion.

Continuing marijuana prohibition forces critically ill people to suffer needlessly, leaves life-changing treatments undeveloped, and keeps patients and providers in limbo between state and federal laws, NCIA Executive Director Aaron Smith said in a statement.


Source: United Press International (August 11, 2016 - 9:09 AM EDT) 

News by QuoteMedia
www.quotemedia.com

Bullboard Posts